COMBAT - A Combination B-and T-Cell Epitope Vaccine to Futureproof COVID-19 Vaccine
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:11 publications
Grant number: 2011044
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$897,133.25Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
Dr. Manisha PandeyResearch Location
AustraliaLead Research Institution
Griffith UniversityResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
We are proposing a vaccine that contains only safe components of the SARS-CoV-2 virus, yet effectively elicits protective immunity. The vaccine works by inducing antibodies capable of preventing the virus from attaching to lung cells, and killer T cells that destroy virus-infected cells. This highly innovative approach will generate a much needed safe and prophylactic 2nd generation modular vaccine, ideal for "vaccine update" that will have a major impact on health and society more generally.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC